This document provides information about the editorial board of the journal Global Drugs and Therapeutics (GDT). GDT is a peer-reviewed, open access journal that considers manuscripts on latest developments in drug discovery and therapy. The editorial board is led by an editor-in-chief, who is currently unlisted, and includes researchers and professors from various universities and countries with expertise in areas related to drug development and therapeutics.
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...Enrique Moreno Gonzalez
Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in
China. Previous experiments have shown that rh-endostatin can inhibit the proliferation and
migration of endothelial cells and some types of tumor cells. In this study, we evaluated the
efficacy and safety profiles of combination therapy of rh-endostatin and neoadjuvant
chemotherapy for breast cancer patients in a prospective, randomized, controlled, phase II
trial.
Pharmacology Forever ! has been set as a meeting in recognition of Frits Peters tremendous involvement in pharmacology. This presentation discusses latest drug development methods and is illustrated by exemple of new drugs and target in oncology.
TOFIQ Journal of Medical Sciences (TJMS) is published by TOFIQ: an NGO registered at the State of Maryland as a non-profit organization dedicated to helping Iraq Higher Education and Research. TJMS is devoted to the publication of original research, commentaries on a current topic, reviews, letters to the editor, and editorials in the field of medical sciences. The early focus of the journal is on clinical burden of disease in Iraq: documentation of its nature and extent; clinical patterns and epidemiology; diagnostic findings; and therapeutic strategies
Tofiq journal of medical sciences vol 3, issue 2 (2016)مجلة توفيق الطبيةTaghreed Al-Noor
TOFIQ Journal of Medical Sciences (TJMS) is published by TOFIQ: an NGO registered at the State of Maryland as a non-profit organization dedicated to helping Iraq Higher Education and Research. TJMS is devoted to the publication of original research, commentaries on a current topic, reviews, letters to the editor, and editorials in the field of medical sciences. The early focus of the journal is on clinical burden of disease in Iraq: documentation of its nature and extent; clinical patterns and epidemiology; diagnostic findings; and therapeutic strategies
Casemix, management, and mortality of patients receiving emergency neurosurge...Ahmad Ozair
Our study included 1635 records from 159 hospitals in 57 countries, collected between Nov 1, 2018, and Jan 31, 2020. 328 (20%) records were from countries in the very high HDI tier, 539 (33%) from countries in the high HDI tier, 614 (38%) from countries in the medium HDI tier, and 154 (9%) from countries in the low HDI tier. The median age was 35 years (IQR 24–51), with the oldest patients in the very high HDI tier (median 54 years, IQR 34–69) and the youngest in the low HDI tier (median 28 years, IQR 20–38). The most common procedures were elevation of a depressed skull fracture in the low HDI tier (69 [45%]), evacuation of a supratentorial extradural haematoma in the medium HDI tier (189 [31%]) and high HDI tier (173 [32%]), and evacuation of a supratentorial acute subdural haematoma in the very high HDI tier (155 [47%]). Median time from injury to surgery was 13 h (IQR 6–32). Overall mortality was 18% (299 of 1635). After adjustment for casemix, the odds of mortality were greater in the medium HDI tier (odds ratio [OR] 2·84, 95% CI 1·55–5·2) and high HDI tier (2·26, 1·23–4·15), but not the low HDI tier (1·66, 0·61–4·46), relative to the very high HDI tier. There was significant between-hospital variation in mortality (median OR 2·04, 95% CI 1·17–2·49).
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...Enrique Moreno Gonzalez
Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in
China. Previous experiments have shown that rh-endostatin can inhibit the proliferation and
migration of endothelial cells and some types of tumor cells. In this study, we evaluated the
efficacy and safety profiles of combination therapy of rh-endostatin and neoadjuvant
chemotherapy for breast cancer patients in a prospective, randomized, controlled, phase II
trial.
Pharmacology Forever ! has been set as a meeting in recognition of Frits Peters tremendous involvement in pharmacology. This presentation discusses latest drug development methods and is illustrated by exemple of new drugs and target in oncology.
TOFIQ Journal of Medical Sciences (TJMS) is published by TOFIQ: an NGO registered at the State of Maryland as a non-profit organization dedicated to helping Iraq Higher Education and Research. TJMS is devoted to the publication of original research, commentaries on a current topic, reviews, letters to the editor, and editorials in the field of medical sciences. The early focus of the journal is on clinical burden of disease in Iraq: documentation of its nature and extent; clinical patterns and epidemiology; diagnostic findings; and therapeutic strategies
Tofiq journal of medical sciences vol 3, issue 2 (2016)مجلة توفيق الطبيةTaghreed Al-Noor
TOFIQ Journal of Medical Sciences (TJMS) is published by TOFIQ: an NGO registered at the State of Maryland as a non-profit organization dedicated to helping Iraq Higher Education and Research. TJMS is devoted to the publication of original research, commentaries on a current topic, reviews, letters to the editor, and editorials in the field of medical sciences. The early focus of the journal is on clinical burden of disease in Iraq: documentation of its nature and extent; clinical patterns and epidemiology; diagnostic findings; and therapeutic strategies
Casemix, management, and mortality of patients receiving emergency neurosurge...Ahmad Ozair
Our study included 1635 records from 159 hospitals in 57 countries, collected between Nov 1, 2018, and Jan 31, 2020. 328 (20%) records were from countries in the very high HDI tier, 539 (33%) from countries in the high HDI tier, 614 (38%) from countries in the medium HDI tier, and 154 (9%) from countries in the low HDI tier. The median age was 35 years (IQR 24–51), with the oldest patients in the very high HDI tier (median 54 years, IQR 34–69) and the youngest in the low HDI tier (median 28 years, IQR 20–38). The most common procedures were elevation of a depressed skull fracture in the low HDI tier (69 [45%]), evacuation of a supratentorial extradural haematoma in the medium HDI tier (189 [31%]) and high HDI tier (173 [32%]), and evacuation of a supratentorial acute subdural haematoma in the very high HDI tier (155 [47%]). Median time from injury to surgery was 13 h (IQR 6–32). Overall mortality was 18% (299 of 1635). After adjustment for casemix, the odds of mortality were greater in the medium HDI tier (odds ratio [OR] 2·84, 95% CI 1·55–5·2) and high HDI tier (2·26, 1·23–4·15), but not the low HDI tier (1·66, 0·61–4·46), relative to the very high HDI tier. There was significant between-hospital variation in mortality (median OR 2·04, 95% CI 1·17–2·49).
Letter: Is the Stupp Protocol an expensive and unsustainable standard of care...Ahmad Ozair
Glioblastoma multiforme (GBM) is the most common and aggressive primary adult brain neoplasm with an age-adjusted incidence rate of 3.22 per 100 000 individuals and a 5-yr survival rate of 6.8%.1 In 2005, Stupp and colleagues proposed maximal safe resection, concomitant temozolomide (TMZ) with radiotherapy, and adjuvant TMZ as the optimal treatment. Implementation of the Stupp protocol in high-income countries (HICs) has resulted in increased survival compared to previous regimens. With little-to-no literature on the management and outcomes of patients with GBM in low- and middle-income countries (LMICs), it is unclear whether the Stupp protocol is being adopted or whether it is, or ever can be, the optimal strategy in LMICs...
Percutaneous image-guided cryoablation of spinal metastases: A systematic reviewAhmad Ozair
Percutaneous cryoablation (PCA) is a minimally invasive technique that has been recently used to treat spinal metastases with a paucity of data currently available in the literature. A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Prospective or retrospective studies concerning metastatic spinal neoplasms treated with current generation PCA systems and with available data on safety and clinical outcomes were included. In the 8 included studies (7 retrospective, 1 prospective), a total of 148 patients (females = 63%) underwent spinal PCA. Tumors were located in the cervical (3/109 [2.8%], thoracic (74/109 [68.8%], lumbar (37/109 [33.9%], and sacrococcygeal (17/109 [15.6%] regions. Overall, 187 metastatic spinal lesions were treated. Thermo-protective measures (e.g., carbo-/hydro-dissection, thermocouples) were used in 115/187 [61.5%] procedures. For metastatic spinal tumors, the pooled mean difference (MD) in pain scores from baseline on the 0–10 numeric rating scale was 5.03 (95% confidence interval [CI]: 4.24 to 5.82) at a 1-month follow-up and 4.61 (95% CI: 3.27 to 5.95) at the last reported follow-up (range 24–40 weeks in 3/4 studies). Local tumor control rates ranged widely from 60% to 100% at varying follow-ups. Grade I-II complications were reported in 9/148 [6.1%] patients and grade III-V complications were reported in 3/148 [2.0%]) patients. PCA, as a stand-alone or adjunct modality, may be a viable therapy in appropriately selected patients with painful spinal metastases who were traditionally managed with open surgery and/or radiation therapy.
Haapalinna the new modalities ecosystem project what is there for meAntti Haapalinna
The aim of this New Modalities Ecosystem is enable improved understanding of disease pathology related to the symptoms and disease progression and better treatments by applying large molecular drugs and diagnostic tools as well as digital wearable patient tools for disease symptom recording, to have real world evidence for treatment efficacy
ROLE OF ECHOGRAPHY AND COMPUTED TOMOGRAPHY IN DIAGNOSIS OF CHRONIC DIFFUSE LI...pbij
In three-stage prospective cohort controlled research of 2876 persons with chronic diffuse liver diseases (2076 cases of fatty liver disease, 509 cases of chronic hepatitis, 139 cases of liver cirrhosis) and 152 healthy controls the clinical significance of radiation methods of investigation in quantitative evaluation of liver morphofunctional state in patients with chronic diffuse liver diseases was estimated. Diagnosisprognostic algorithm for patients with this pathology was developed, validated and recommended for practical application. Further perspectives are related to detailed chronic diffuse liver diseases stratification by intensity of steatosis (in fatty liver disease), activity (in chronic hepatitis) and fibrosis (in chronic hepatitis and liver cirrhosis).
Perceived benefits and barriers to exercise for recently treated patients wit...Enrique Moreno Gonzalez
Understanding the physical activity experiences of patients with multiple myeloma (MM) is essential to inform the development of evidence-based interventions and to quantify the benefits of physical activity. The aim of this study was to gain an in-depth understanding of the physical activity experiences and perceived benefits and barriers to physical activity for patients with MM.
Over view to an event tailored to India’s burgeoning modern hospitality sector that seeks to invigorate the market and unify the industry, building trade links and a national community.
Letter: Is the Stupp Protocol an expensive and unsustainable standard of care...Ahmad Ozair
Glioblastoma multiforme (GBM) is the most common and aggressive primary adult brain neoplasm with an age-adjusted incidence rate of 3.22 per 100 000 individuals and a 5-yr survival rate of 6.8%.1 In 2005, Stupp and colleagues proposed maximal safe resection, concomitant temozolomide (TMZ) with radiotherapy, and adjuvant TMZ as the optimal treatment. Implementation of the Stupp protocol in high-income countries (HICs) has resulted in increased survival compared to previous regimens. With little-to-no literature on the management and outcomes of patients with GBM in low- and middle-income countries (LMICs), it is unclear whether the Stupp protocol is being adopted or whether it is, or ever can be, the optimal strategy in LMICs...
Percutaneous image-guided cryoablation of spinal metastases: A systematic reviewAhmad Ozair
Percutaneous cryoablation (PCA) is a minimally invasive technique that has been recently used to treat spinal metastases with a paucity of data currently available in the literature. A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Prospective or retrospective studies concerning metastatic spinal neoplasms treated with current generation PCA systems and with available data on safety and clinical outcomes were included. In the 8 included studies (7 retrospective, 1 prospective), a total of 148 patients (females = 63%) underwent spinal PCA. Tumors were located in the cervical (3/109 [2.8%], thoracic (74/109 [68.8%], lumbar (37/109 [33.9%], and sacrococcygeal (17/109 [15.6%] regions. Overall, 187 metastatic spinal lesions were treated. Thermo-protective measures (e.g., carbo-/hydro-dissection, thermocouples) were used in 115/187 [61.5%] procedures. For metastatic spinal tumors, the pooled mean difference (MD) in pain scores from baseline on the 0–10 numeric rating scale was 5.03 (95% confidence interval [CI]: 4.24 to 5.82) at a 1-month follow-up and 4.61 (95% CI: 3.27 to 5.95) at the last reported follow-up (range 24–40 weeks in 3/4 studies). Local tumor control rates ranged widely from 60% to 100% at varying follow-ups. Grade I-II complications were reported in 9/148 [6.1%] patients and grade III-V complications were reported in 3/148 [2.0%]) patients. PCA, as a stand-alone or adjunct modality, may be a viable therapy in appropriately selected patients with painful spinal metastases who were traditionally managed with open surgery and/or radiation therapy.
Haapalinna the new modalities ecosystem project what is there for meAntti Haapalinna
The aim of this New Modalities Ecosystem is enable improved understanding of disease pathology related to the symptoms and disease progression and better treatments by applying large molecular drugs and diagnostic tools as well as digital wearable patient tools for disease symptom recording, to have real world evidence for treatment efficacy
ROLE OF ECHOGRAPHY AND COMPUTED TOMOGRAPHY IN DIAGNOSIS OF CHRONIC DIFFUSE LI...pbij
In three-stage prospective cohort controlled research of 2876 persons with chronic diffuse liver diseases (2076 cases of fatty liver disease, 509 cases of chronic hepatitis, 139 cases of liver cirrhosis) and 152 healthy controls the clinical significance of radiation methods of investigation in quantitative evaluation of liver morphofunctional state in patients with chronic diffuse liver diseases was estimated. Diagnosisprognostic algorithm for patients with this pathology was developed, validated and recommended for practical application. Further perspectives are related to detailed chronic diffuse liver diseases stratification by intensity of steatosis (in fatty liver disease), activity (in chronic hepatitis) and fibrosis (in chronic hepatitis and liver cirrhosis).
Perceived benefits and barriers to exercise for recently treated patients wit...Enrique Moreno Gonzalez
Understanding the physical activity experiences of patients with multiple myeloma (MM) is essential to inform the development of evidence-based interventions and to quantify the benefits of physical activity. The aim of this study was to gain an in-depth understanding of the physical activity experiences and perceived benefits and barriers to physical activity for patients with MM.
Over view to an event tailored to India’s burgeoning modern hospitality sector that seeks to invigorate the market and unify the industry, building trade links and a national community.
This is a little overview of myself. It will tell people who don't know me learn some background information about me. This is a visual that will tell you who I am and what kind of person I am.
Test kratownicy z Politechniki Krakowskiej. Metoda równoważenia węzłów, metoda Rittera, Metoda Cremony.
Prezentacja zawiera tylko zestawienie wyników. Pełny projekt można wygenerować na:
www.gruparectan.com
Więcej info:
www.facebook.com/rectanbudownictwo
lub pod adresem:
gruparectan@gmail.com
Zakres: Mechanika Ogólna, Wytrzymałość Materiałów, Mechanika Budowli.
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van GoolAlain van Gool
Keynote lecture at the Pharma-Nutrition 2015 conference, outline global paradigm shifts and activities in pharma, personalized healthcare and pharmanutrition combination therapies.
Enfermedad minoritaria, terapias nuevas. Una patología que afecta a menos de cinco personas por cada 10.000 habitantes es considerada una enfermedad rara o minoritaria. 35 millones de europeos se ven afectados por alguna de ellas. El 80% son de origen genético y conseguir un diagnóstico rápido es vital para asegurar la calidad de vida futura. La clave, una vez más, es apostar y potenciar la investigación biomédica. Se revisarán los resultados obtenidos los últimos 14 años, en el marco científico y regulador impulsado por la UE desde el año 2000. Sin embargo, se analizarán las dificultades y oportunidades para impulsar la investigación traslacional en estas enfermedades.
Sigue la presentación en Youtube: https://www.youtube.com/watch?v=d4U4a8xFCzA&
Ségolème Aymé - Infraestructuras de I + D para impulsar investigación en Enfe...Fundación Ramón Areces
El 29 de octubre de 2014, la Fundación Ramón Areces celebró una nueva conferencia del ciclo de Enfermedades Raras organizado con el Vall d'Hebron Institute of Research de Barcelona. En esta ocasión, Ségolène Aymé, directora emérita de investigación del INSERM, fundadora de Orphanet y presidenta del Grupo Consultivo Temático sobre Enfermedades Raras en la OMS, habló sobre 'Las infraestructuras de I+D necesarias para impulsar la investigación en Enfermedades Raras'. Antes de su intervención, explicó en esta entrevista cómo mejorar las políticas de investigación en patologías poco frecuentes.
4th International Conference on Biomarkers & Clinical Research, will be organized around the theme "Impact of Biomarker Developments in Health Diagnostics and Clinical Research."
The benefits of patient involvement in research and development (RE:ACT Congr...jangeissler
Presentation of Jan Geissler, Director EUPATI and Co-Founder CML Advocates Network, about the benefits of involving patients in research and development, and about EUPATI. Held at RE:ACT Conress 2016 on Research of Rare and Orphan Diseases, organized by the Blackswan Foundation on 12 March 2016 in Barcelona, Spain
The most complete map of oncogenes to date a summary of 568 oncogenes in 66 c...DoriaFang
By analyzing the genomes of 28,076 tumor samples from 66 types of cancer, 568 cancer driver genes were identified. This is the most complete map of cancer driver genes to date. The research data has been updated on the IntOGen platform.
NIH Drug Discovery and Development - NCTT and CTSAsCTSI at UCSF
Presented at the UC Braid Retreat: Imagine a statewide research engine of pooled resources, data, and expertise that accelerates the “translation” of academic research to direct patient benefit. That's the goal of the University of California Biomedical Research Acceleration, Integration, and Development (UC BRAID) program.
Translational Genomics towards Personalized medicine - Medhavi Vashisth.pptMedhavi27
Every individual is unique, and so is his/her body's affinity and reaction towards diseases and their treatment methods. The science of personalized takes into account biology of one individual at a time and relates it with established databases for devising or optimizing suitable treatment strategies.
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...Office of Health Economics
The Biotherapy Development Association convened a two-day workshop in January 2014 to assess access to innovative cancer medicines in Europe. This presentation by OHE's Adrian Towse covers the situation in England, examining challenges that are peculiar to England as well as the English experience with issues common across countries.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
A brief information about the SCOP protein database used in bioinformatics.
The Structural Classification of Proteins (SCOP) database is a comprehensive and authoritative resource for the structural and evolutionary relationships of proteins. It provides a detailed and curated classification of protein structures, grouping them into families, superfamilies, and folds based on their structural and sequence similarities.
1. Loutfy Hamid Madkour
Editorial Board
Global Drugs and Therapeutics (GDT)
https://oatext.com/Global-Drugs-and-Therapeutics-GDT.php#Editorial_Board
Home
Contact Us
Follow us on :
About us
About Us
Providing cutting-edge scholarly communications to worldwide, enabling them to utilize available resources effectively
Read More
About Us
Our Mission
Our Vision
Strategic Goals and Objectives
Open Access
News and events
Contact Us
For Authors
For Authors
We aim to bring about a change in modern scholarly communications through the effective use of editorial and publishing polices.
Read More
Authors’ Charter
Guidelines for Authors
o Article Types & Format
2. o Supplemental Material
o Submission, Review, & Decision
o Publication Charges
o Withdrawal Policy
Submission Instructions
o Manuscript Preparation
o Figure Preparation
o Table Preparation
o Supplemental Material & Data
o Reference Style Guide
Editorial & Publishing Policies
o Publication Ethics
o Authorship & Author Responsibilities
o Copyright & License Agreements
o Competing Interests
o Overlapping Publication
o Confidentiality & Anonymity
o Corrections & Retraction
o Obligation to Register Clinical Trials
o Plagiarism
o Due Credit
Resources
Resources
OA Text’s journals are led by prominent researchers, each embracing the concept that basic knowledge can foster sustainable
solutions for society.
Read More
Guidelines for Editor-in-chief
Guidelines for Editors
Guidelines for Reviewers
Special Issues
Frequently Asked Questions
Journals
o Integrative Molecular Medicine (IMM)
o Global Dermatology (GOD)
o Integrative Cancer Science and Therapeutics (ICST)
o Journal of Integrative Cardiology (JIC)
o Integrative Pharmacology, Toxicology and Genotoxicology (IPTG)
3. o Integrative Food, Nutrition and Metabolism (IFNM)
o Dental, Oral and Craniofacial Research (DOCR)
o Clinical Research and Trials (CRT)
o Integrative Obesity and Diabetes (IOD)
o Global Anesthesia and Perioperative Medicine (GAPM)
o Contemporary Behavioral Health Care (CBHC)
o Fractal Geometry and Nonlinear Analysis in Medicine and Biology (FGNAMB)
o Clinical Case Reports and Reviews (CCRR)
o Clinical Obstetrics, Gynecology and Reproductive Medicine (COGRM)
o Journal of Translational Science (JTS)
o New Frontiers in Ophthalmology (NFO)
o Clinical Proteomics and Bioinformatics (CPB)
o Journal of Systems and Integrative Neuroscience (JSIN)
o Clinical and Diagnostic Pathology (CDP)
o Endocrinology, Metabolism & Genetics (EMG)
o Vascular Diseases and Therapeutics (VDT)
o Global Drugs and Therapeutics (GDT)
o Oral Health and Care (OHC)
o General Internal Medicine and Clinical Innovations (GIMCI)
o Frontiers in Nanoscience and Nanotechnology (FNN)
o Global Vaccines and Immunology (GVI)
o Global Hormonal Health (GHH)
o Pediatric Dimensions (PD)
o Pulmonary and Critical Care Medicine (PCCM)
o Translational Brain Rhythmicity (TBR)
o Biomedical Research and Clinical Practice (BRCP)
o Biomaterials and Tissue Technology (BTT)
o Trauma and Emergency Care (TEC)
o Nursing and Palliative Care (NPC)
o Global Surgery (GOS)
o Frontiers in Women’s Health (FWH)
o Advanced Material Science (AMS)
o Clinical Microbiology and Infectious Diseases (CMID)
o Interdisciplinary Journal of Chemistry (IJC)
o Mental Health and Addiction Research (MHAR)
o Biomedical Genetics and Genomics (BGG)
o Global Imaging Insights (GII)
o Medical Devices and Diagnostic Engineering (MDDE)
o Biology, Engineering and Medicine (BEM)
o Liver and Pancreatic Sciences (LPS)
o Histology, Cytology and Embryology (HCE)
4. o Forensic Science and Criminology (FSC)
o Journal of Medicine and Therapeutics (JMT)
o Otorhinolaryngology Head and Neck Surgery (OHNS)
o Nuclear Medicine and Biomedical Imaging (NMBI)
o Journal of Stem Cell Research and Medicine (JSCRM)
o Physical Medicine and Rehabilitation Research (PMRR)
o Gastroenterology, Hepatology and Endoscopy (GHE)
o Clinical and Medical Investigations (CMI)
o Health Education and Care (HEC)
o Transplantation-Open (TO)
o Hematology & Medical Oncology (HMO)
o Cancer Reports and Reviews (CRR)
o Biomarkers & Genes (BG)
o Cardiovascular Disorders and Medicine (CDM)
o Molecular Biophysics and Biochemistry (MBB)
o Rheumatology and Orthopedic Medicine (ROM)
o Virology: Research & Reviews (VRR)
o Neurological Disorders and Therapeutics (NDT)
o Journal of Spine Care (JSC)
o Nephrology and Renal Diseases (NRD)
o Alzheimer's, Dementia & Cognitive Neurology (ADCN)
o Pharmacology, Drug Development & Therapeutics (PDDT)
o Fetal, Neonatal and Developmental Medicine (FNDM)
o Hypertension Current Concepts and Therapeutics (HCCT)
o Fisheries, Aquaculture and Aquatic Sciences (FAAS)
o Earth Science and Climatology (ESC)
Links
Links
Advanced knowledge sharing through global community…
Read More
Links
o Associations & Collaborations
Global Drugs and Therapeutics (GDT)
About Journal
Editor-in-Chief
Editorial Board
5. Early View
Current Issue
Previous Issue
Archive
Submit Manuscript
Publication Charges
Global Drugs and Therapeutics (GDT)
Global Drugs and Therapeutics (GDT) is a bimonthly, open access, peer-reviewed journal which
considers manuscripts on latest developments in drug discovery and therapy
GDT is a novel journal that will include: Pharmaceutical Research & Development, Translational
Medicine, Regenerative Medicine, Enabling Technologies, Structural Biology, Drug Delivery &
Targeting, Antiinfectives, Biologics, CNS Drug Discovery & Therapy, Diabetes and Obesity Drug
Discovery & Therapy, Women's Health Drug Discovery & Therapy, Drug Discovery in Preclinical
Research, Cardiovascular Drug Discovery & Therapy, Oncology, Process Chemistry and Drug
Manufacturing, Pulmonary Drug Discovery & Therapy, Recent Advances in Patient Treatment and
Care, Inflammation and Immunology, Innovative Drug Discovery and Nanotechnology, Pharmaceutical
Biotechnology, Proteomics & Bioinformatics, Pharmacogenomics, Protein and Peptide Sciences, Drug
Metabolism, Hot Topics in Medicinal Chemistry, Medical Imaging, Hot Topics in HIV Research, In-
silico Drug Design and in-silico screening, Combinatorial Chemistry, High-throughput Screening &
Laboratory automation, Hot Topics in Drug Targets, Hot Topics in Natural Products, Stereoselective Synthesis of Bioactive
Compounds, Recent Advances in Spectroscopy, Academic CRO/Industrial collaborations in drug discovery.
Manuscripts may take the form of original empirical research, critical reviews of the literature, brief commentaries, meeting reports,
case reports, innovations in clinical practice, letters and drug clinical trial studies.
GDT welcomes direct submissions from authors: Attach your word file with e-mail and send it to:
submissions@oatext.com alternatively to: editor.gdt@oatext.com
Please, follow the Instructions for Authors. In the cover letter add the name and e-mail address of 5 proposed reviewers (we can
choose them or not).
Copyright is retained by the authors and articles can be freely used and distributed by others. Articles are distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work, first published by GDT, is properly cited
Editor in chief
Will be updated soon.
Editorial Board
Costas Demetzos Ph.D
Professor in Pharmaceutical Nanotechnology
Director of the Department of Pharmaceutical Technology
National and Kapodistrian University of Athens
Greece
Violet Kasabri Ph.D
Associate Professor
Department of Pharmacy and biomedical sciences
University of Jordan
Jordan
Natassa Pippa Ph.D
6. Researcher
Department of Pharmaceutical Technology
National and Kapodistrian University of Athens
Greece
Giuseppe De Rosa
Professor
Department of Pharmacy
University of Naples Federico II
Italy
Kexin Liu
Professor
Department of Pharmaceutics
Dalian Medical University, Dalian,
China
Yukio Yoneda, PhD
Professor Emeritus
Kanazawa University
Section of Prophylactic Pharmacology
Venture Business Laboratory 402
Kakuma-machi
Kanazawa, Ishikawa, Japan
Pierre Guertin, Ph.D
Senior Chief Executive
Professor
Psychiatry & Neurosciences
Laval University
Québec City
Canada
Purnendu Kumar Sharma
Research Assistant, 104 Faser Hall
Department of Pharmaceutics and Drug Delivery School of Pharmacy
University of Mississippi~ Olemiss
Oxford-University
USA
Sinerik Ayrapetyan
Head Research Council
UNESCO Chair-Life Sciences International Postgraduate Educational Center
Yerevan
Armenia
Pedro Joao Neves Miranda de Castro
Professor
Department of Pharmacy
Rua Mestre Guilherme Camarinha
Porto, Portugal
Flávia Cristina Moreira de Sousa
7. Researcher
Department of Fonseca Pharmacy
University of Porto
Portugal
Dejan Radovanovic, MD
Department of Health Sciences
School of Respiratory Diseases
University of Milan
Milan, Italy
Hirai Takao
Associate Professor
Laboratory of Medicinal Resources
School of Pharmacy, Aichi-Gakuin University
Japan
Gian Maria Pacifici
Associate Professor
Department of Pharmacology
University of Pisa
Pisa, Italy
Simona Collina
Associate professor
Head of Medicinal Chemistry Laboratory
Department of Drug Sciences
University of Pavia
Italy
Simona Daniele
Senior researcher
Department of Pharmacy
University of Pisa
Italy
Francesco Marampon
Professor
Department of Applied Clinical Sciences and Biotechnology
University of L’Aquila
Italy
Gianluca Manni
Professor
Department of Opthamology
University of Rome Tor Vergata
Italy
Antonio Siniscalchi
Neurologist
Department of Neurology
Annunziata Hopsital
Cosenza
Italy
8. Valeria Pittalà
Assistant Professor
Department of Drug Science
Section of Medicinal Chemistry
University of Catania
Italy
Gianfranco Balboni
Associate Professor
Department of medicinal chemistry
University of Ferrara
Italy
Raffaele Pilla
Researcher
Department of Medicine and Surgery
University of Salerno
Italy
Loutfy Hamid Madkour
Professor
Department of Physical Chemistry and Electro Analytical Chemistry
Al Baha University
Saudi Arabia
Pedro Ricardo Martins Lopes da Fonte
Professor
Department of Pharmacy
University of Porto
Portugal
Carla Carnovale
Professor
Department of Clinical Pharmacology
University of Milan
Italy
Fabio Del Bello
Researcher
Department of medicinal chemistry
University of Camerino
Italy
Salvatore Giunta
Professor
Department of Biomedical and Biotechnological Sciences
Human Anatomy and Histology Section
School of Medicine, University of Catania
Italy
Antonio Simone Laganà M.D.
Unit of Gynaecology and Obstetrics
Department of Human Pathology in Adulthood and Childhood “G. Barresi”
9. University of Messina
Italy
Mosab Arafat
Assistant Professor
Al Ain University of Science and Technology
New Zealand
Early View
Will be updated soon.
Current Issue
Will be updated soon.
Previous Issue
Will be updated soon.
Archive
Will be updated soon.
Submit Manuscript
GDT welcomes direct submissions from authors: Attach your word file with e-mail and send it to:
submissions@oatext.com alternatively to: editor.gdt@oatext.com
Publication Charges
Article Publication Charges (APC)
OA Text journals are open access, we do not charge the end user when accessing a manuscript or any article. This allows the scientific
community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the
term of"Creative Commons Attribution License". In line with other open access journals we provide a flat fee submission structure
(dependent upon the journal) on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway
(the article processing charge). The process includes our maintenance, submission and peer review systems and international editing,
publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and
associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically,
legally and financially stable.
1. What are your publication charges?
2. Why are your charges set at these levels?
3. When do I pay Article Publication Charges?
1. What are your publication charges?
The costs of producing and maintaining OA Text are recovered by charging a publication fee to authors or research sponsors for each
article that they publish.
Journal Publication Fee (GBP / USD)
Integrative Molecular Medicine (IMM) £690 / $890
Global Dermatology (GOD) £690 / $890
Integrative Cancer Science and Therapeutics (ICST) £690 / $890
10. Journal of Integrative Cardiology (JIC) £690 / $890
Integrative Pharmacology, Toxicology and Genotoxicology (IPTG) £690 / $890
Integrative Food, Nutrition and Metabolism (IFNM) £690 / $890
Dental, Oral and Craniofacial Research (DOCR) £690 / $890
Clinical Research and Trials (CRT) £690 / $890
Integrative Obesity and Diabetes (IOD) £690 / $890
Global Anesthesia and Perioperative Medicine (GAPM) £690 / $890
Contemporary Behavioral Health Care (CBHC) £690 / $890
Fractal Geometry and Nonlinear Analysis in Medicine and Biology (FGNAMB) £0
Clinical Case Reports and Reviews (CCRR) £690 / $890
Clinical Obstetrics, Gynecology and Reproductive Medicine (COGRM) £690 / $890
Global Surgery (GOS) £690 / $890
Journal of Translational Science (JTS) £690 / $890
New Frontiers in Ophthalmology (NFO) £690 / $890
Clinical Proteomics and Bioinformatics (CPB) £690 / $890
Journal of Systems and Integrative Neuroscience (JSIN) £690 / $890
General Internal Medicine and Clinical Innovations (GIMCI) £690 / $890
Frontiers in Nanoscience and Nanotechnology (FNN) £690 / $890
Global Vaccines and Immunology (GVI) £690 / $890
Global Hormonal Health (GHH) £690 / $890
Pediatric Dimensions (PD) £690 / $890
Pulmonary and Critical Care Medicine (PCCM) £690 / $890
Translational Brain Rhythmicity (TBR) £690 / $890
Biomedical Research and Clinical Practice (BRCP) £690 / $890
Biomaterials and Tissue Technology (BTT) £690 / $890
Trauma and Emergency Care (TEC) £690 / $890
Nursing and Palliative Care (NPC) £690 / $890
Frontiers in Women’s Health (FWH) £690 / $890
Advanced Material Science (AMS) £690 / $890
Clinical Microbiology and Infectious Diseases (CMID) £690 / $890
Interdisciplinary Journal of Chemistry (IJC) £690 / $890
Mental Health and Addiction Research (MHAR) £690 / $890
Biomedical Genetics and Genomics (BGG) £690 / $890
Energy Research and Applications (ERA) £690 / $890
Otorhinolaryngology Head and Neck Surgery (OHNS) £690 / $890
Nuclear Medicine and Biomedical Imaging (NMBI) £690 / $890
Journal of Stem Cell Research and Medicine (JSCRM) £690 / $890
Physical Medicine and Rehabilitation Research (PMRR) £690 / $890
Hematology & Medical Oncology (HMO) £690 / $890
Clinical and Medical Investigations (CMI) £690 / $890
Medical Devices and Diagnostic Engineering (MDDE) £690 / $890
Vascular Diseases and Therapeutics (VDT) £690 / $890
Global Imaging Insights (GII) £130 / $150
Hematology & Medical Oncology (HMO) £690 / $890
* Authors who lack the funds to cover publication fees may request a waiver. In order to keep publication charges as low as possible,
fee waivers are not automatically given but must be approved on a case-by-case basis, and authors from developing and transitional
countries are given priority.
Note:Fractal Geometry and Nonlinear Analysis in Medicine and Biology (FGNAMB) Journal doesn’t have any publication
charges.